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Objective: To evaluate relationships between apolipoprotein B (Apo B), LDL cholesterol (LDL-C), and non-
HDL-C in high-risk patients treated with lipid-lowering therapy.
Design and methods: This post-hoc analysis calculated LDL-C and non-HDL-C levels corresponding to an
Apo B of 0.9 g/L following treatment with 1) statin monotherapy (baseline) and 2) ezetimibe/simvastatin 10/
20 mg or rosuvastatin 10 mg (study end). The percentages of patients reaching LDL-C, non-HDL-C, and Apo B
targets were calculated at study end.
Results: After switching to ezetimibe/simvastatin or rosuvastatin, the LDL-C and non-HDL-C
corresponding to Apo B=0.9 g/L were closer to the more aggressive LDL-C and non-HDL-C goals (1.81 and
2.59 mmol/L, respectively). Only slightly N50% of the patients who reachedminimum recommended LDL-C or
non-HDL-C at study end also had an Apo B level b0.9 g/L with both treatments.
Conclusion: The use of Apo B for monitoring the efﬁcacy of lipid-altering therapy would likely lead to
more stringent criteria for lipid lowering.© 2011 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.Introduction
Both national and international guidelines identify low-density
lipoprotein cholesterol (LDL-C) as the primary treatment target for
reducing coronary heart disease (CHD) risk in patients with hypercho-
lesterolemia [1,16,18,29]. Cholesterol management guidelines endorseing for this study was provided
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ociety of Clinical Chemists. Publisha minimum LDL-C goal of b2.59 mmol/L in high risk patients with an
optional target of b1.99 or b1.81 mmol/L in persons at very high risk of
CHD [1,16,18,29]. Some patients with lipoprotein abnormalities,
particularly those with increased triglyceride (TG) levels, may have
excess levels of other apolipoprotein (Apo) B-containing lipoproteins
(e.g., very low-density lipoprotein, intermediate-density lipoprotein,
lipoprotein (a), and a preponderance of cholesterol-depleted, small,
dense LDL particles), which confer additional atherogenic risk beyond
that represented by LDL-C alone [8]. In such patients, non-high-density
lipoprotein cholesterol (non-HDL-C; i.e., the sum of cholesterol carried
by chylomicrons, very low-density lipoprotein, intermediate-density
lipoprotein plus LDL) may be a more accurate predictor of CHD risk
compared with LDL-C, especially among patients receiving statin
therapy [2,15,19].
Apo B is another parameterwith proven utility in assessing CHD risk
[8]. Apo B is a reliable measure of the total number of atherogenic
particles in theblood streamsince eachatherogenic lipoprotein contains
a single molecule of Apo B [26,32]. Several studies have shown that Apo
B is a more accurate parameter for assessing CHD risk compared with
LDL-C [15,22,25,27,34,36]. LDL-C is inadequate at assessing the totaled by Elsevier Inc. All rights reserved.
628 H. Vaverkova et al. / Clinical Biochemistry 44 (2011) 627–634concentration of atherogenic particles particularly among high-risk
patients who frequently have a preponderance of cholesterol-depleted,
small, dense LDL particles [3,17,21,31].
To this end, the consensus statement issued by the American
Diabetes Association (ADA) and the American College of Cardiology
(ACC) Foundation identiﬁes non-HDL-C and apo B as co-primary targets
of therapy in high cardiometabolic risk patients [8]. Non-HDL-C goals of
3.37 and b2.59 mmol/L and apo B goals ofb0.9 g/L and 0.8 g/L are
recommended for high-risk and very high-risk individuals, respectively
[8].
The use of Apo B in clinical practice to guide patient management is
not widespread. The main reason is probably because Apo B is not
currently recommended as a primary screening parameter by most
international and national lipid treatment guidelines. Non-HDL-C and
Apo B have been shown to correlate relatively strongly both in non-
treated and statin-treated patients, although the strength of these
associations varies depending on the population studied [4,6,24,28,33].
As a result, some have proposed using non-HDL-C as a surrogate
measure of Apo B, thus obviating the need to introduce a new assay into
the standard lipid panel [6].
Previous literature demonstrated that statins provide larger
reductions in plasma LDL-C levels and result in a lowering of LDL-C
to lower population percentile level than that seen for Apo B
[4,6,9,10,30]. Thus, the use of LDL-C as the sole parameter in guiding
the management of statin-treated patients may result in the
underachievement of recommended non-HDL-C and most especially
Apo B targets, thereby placing patients at unnecessary risk [7,8].
Although three recent studies evaluated the effects of statin therapy
on the correlations between Apo B:LDL-C and Apo B:non-HDL-C
[4,6,9], relatively little is known about the effects of other lipid-
altering therapies on these correlations.
This post-hoc analysis of a previously published study [12] evaluated
the relationship of Apo B with LDL-C and non-HDL-C values in a
population of 618 high-risk hypercholesterolemic patients (i.e., deﬁned
byprior history of CHD; type 2 diabeteswith high cardiovascular risk; or
10 year Framingham risk, N20%) who did not achieve their LDL-C goals
while taking a stable dose of open-label statin monotherapy. Following
6 weeks of treatment with statin monotherapy, patients with LDL-C
N2.59 mmol/L were switched to double-blind ezetimibe/simvastatin
(EZE/SIMVA) 10/20 mg or rosuvastatin (ROSUVA) 10 mg for 6 weeks.
Both EZE/SIMVA 10/20 mg and ROSUVA 10 mg were chosen for use in
this study because they were expected to show greater LDL-C-lowering
efﬁcacy compared with the statins used at baseline. This analysis
evaluated the correlations between Apo B and LDL-C or non-HDL-C
following 1) 6 weeks of open-label treatment with statin monotherapy
(i.e., baseline) and 2) 6 weeks of double-blind treatment with EZE/
SIMVA 10/20 mg or ROSUVA 10 mg (i.e., study end). Simple linear
regression (SLR) analyses were also performed at baseline and study
end to evaluate the LDL-C and non-HDL-C values that are equivalent to
the recommended Apo B targets of b0.9 and b0.8 g/L. Additional
analyses were performed in patient subgroups deﬁned by baseline TG
values (i.e., TG, b and N2.26 mmol/L) and relative potency of the pre-
randomization statin monotherapy (i.e., low and high). Analyses were
performed to evaluate the proportions of patients reaching LDL-C, non-
HDL-C, and Apo B targets.
Methods
Patients and study design
Full details of the methods of the INCROSS study are reported
elsewhere [12]. In this multicenter, randomized, double-blind trial,
active-controlled, parallel group study, 618 patients with documented
hypercholesterolemia (LDL-C, 2.59–4.92 mmol/L at the screening visit
and 2.59–4.14 mmol/L at the randomization visit) and high
cardiovascular risk whowere taking a stable daily dose of one of severalstatin medications for N6 weeks prior to the study randomization visit
entered a 6 week open-label stabilization/screening period during
which they continued to receive their pre-study statin dose. Patients
were deemed to beof high cardiovascular risk if theymet oneormore of
the following criteria: (i) history of CHD (i.e., stable andunstable angina,
revascularization procedure, myocardial infarction, documented
myocardial ischemia) or with established vascular atherosclerotic
disease (i.e., peripheral vascular disease, ischemic stroke); (ii) type 2
diabetes without a history of vascular disease and with high
cardiovascular risk (i.e., renal impairment [proteinuria, N300 mg/24 h,
or creatinine clearance standardized for body surface area, b1.002 mL/s]
and/or at least 2 CHD risk factors per Framingham risk calculation);
(iii) CHD risk N20% over 10 years as determined by Framingham risk
calculation. Fasting TG levels had to be b3.96 mmol/L 1 week prior to
the randomization visit (i.e., week 0/baseline) to allow for the
calculation of LDL-C by the Friedewald equation.
Patients who did not achieve their minimum recommended LDL-C
goals (i.e., b2.59 mmol/L) after taking a stable dose (N6 weeks) of open-
label statin monotherapy were stratiﬁed by study site and potency of
their pre-randomization statin brand/dose (low [stratum1: atorvastatin,
10 mg; ﬂuvastatin, 80 mg; lovastatin, 20 mg; pravastatin, 40 mg;
simvastatin,20 mg]orhigh [stratum2: atorvastatin,20 mg; rosuvastatin,
5 mg; simvastatin, 40 mg]) and subsequently randomized in equal
proportions to receive double-blind EZE/SIMVA 10/20 mg (n=314) or
ROSUVA 10 mg (n=304) for 6 weeks. Both these treatments represent
starting doses of more potent lipid-lowering therapies, and according to
the product labels, should yield similar LDL-C reductions.
As previously described, the primary efﬁcacy endpoint for this study
was the percentage change from baseline (i.e., week 0) to study
endpoint (i.e., last post baseline measurement during the 6 week active
treatment period) in LDL-C. Secondary efﬁcacymeasurements included
the proportion of patients achieving LDL-C goals (b2.59 and
b1.81 mmol/L) as well as the mean percentage changes from baseline
in total cholesterol, TG, HDL-C, non-HDL-C, and Apo B after 6 weeks of
treatment.
The study was conducted in accordance with principles of Good
Clinical Practice and was approved by the appropriate institutional
review boards and regulatory agencies, and all patients provided
written informed consent.
Laboratory methods
All analyses were conducted on fasting blood samples at a certiﬁed
central laboratory (MRLI, Brussels, Belgium) according to standards
speciﬁed by the National Heart Lung and Blood Institute and Centers
for Disease Control and Prevention [23]. Plasma concentrations of TC,
TG, and HDL-C were quantiﬁed enzymatically using the Hitachi 747
analyzer (Roche Diagnostics Corporation, Indianapolis, IN). LDL-C
levels were calculated using the equation of Friedewald et al. [LDL-
C=TC−HDL-C−(TG/2.2)] [14]. Ultracentrifugation was used to
measure LDL-C values in patients with TG N4.5 mmol/L. HDL-C was
quantiﬁed enzymatically after the removal of Apo B-containing
lipoproteins by heparin and manganese chloride precipitation
[20,37]. Non-HDL-C levels were calculated by subtracting HDL-C
from TC values. Apo B concentrations in whole plasmaweremeasured
by immunonephelometry using a Dade Behring GmbH Nephelometer
(Marburg, Germany) [13]. International Federation of Clinical
Chemistry (IFCC) standards were used to calibrate the Apo B
measurements.
Statistical analyses
The current report describes the results of a post-hoc exploratory
analysis performed to evaluate the relationship betweenApoB and LDL-
C or non-HDL-C following (i) 6 weeks of open-label treatment with
statin monotherapy (i.e., baseline/week 0) and (ii) 6 weeks of double-
Table 1
Summary of baseline characteristics and lipid values for overall analysis cohort (FAS)
presented by treatment group.
EZE/SIMVA 10/20 mg;
N=305
ROSUVA 10 mg;
N=297
Demographic parameters
Mean age (SD), years
Overall analysis cohort 63.3 (9.9) 63.1 (10.1)
TG, b2.26 mmol/L 63.9 (10.1) [n=253] 63.1 (10.2) [n=250]
TG, ≥2.26 mmol/L 60.3 (8.4) [n=52] 62.7 (9.2) [n=47]
Females, n (%)
Overall analysis cohort 125 (41.0) 117 (39.4)
TG, b2.26 mmol/L 108 (42.7) [n=253] 94 (37.6) [n=250]
TG, ≥2.26 mmol/L 17 (32.7) [n=52] 23 (48.9) [n=47]
Mean body weight (SD), kg
Overall analysis cohort 78.6 (15.7) 79.4 (14.3)
TG, b2.26 mmol/L 77.3 (15.8) [n=253] 78.3 (14.0) [n=250]
TG, ≥2.26 mmol/L 85.0 (13.8) [n=52] 84.9 (14.7) [n=47]
Mean body mass index (SD),
kg/m2
Overall analysis cohort 28.1 (4.8) 28.0 (4.6)
TG, b2.26 mmol/L 27.7 (4.8) [n=253] 27.5 (4.4) [n=250]
TG, ≥2.26 mmol/L 29.9 (4.1) [n=51] 30.7 (4.7) [n=47]
History of diabetes, n (%)
Overall analysis cohort 89 (29.2) 76 (25.6)
TG, b2.26 mmol/L 62 (24.5) [n=253] 60 (24.0) [n=250]
TG, ≥2.26 mmol/L 27 (51.9) [n=52] 16 (34.0) [n=47]
History of CHD, n (%)
Overall analysis cohort 148 (48.5) 140 (47.1)
TG, b2.26 mmol/L 126 (49.8) [n=253] 119 (47.6) [n=250]
TG, ≥2.26 mmol/L 22 (42.3) [n=52] 21 (44.7) [n=47]
Baseline lipid values
Mean LDL-C (SD), mmol/L
Overall analysis cohort 3.2 (0.4) 3.2 (0.4)
TG, b2.26 mmol/L 3.2 (0.4) [n=253] 3.2 (0.4) [n=250]
TG, ≥2.26 mmol/L 3.3 (0.4) [n=52] 3.3 (0.4) [n=47]
Mean total cholesterol (SD),
mmol/L
Overall analysis cohort 5.4 (0.6) 5.4 (0.6)
TG, b2.26 mmol/L 5.3 (0.5) [n=253] 5.3 (0.6) [n=250]
TG, ≥2.26 mmol/L 5.8 (0.6) [n=52] 5.8 (0.6) [n=47]
Median TG (SD), mmol/L
Overall analysis cohort 1.5 (0.8) 1.4 (0.8)
TG, b2.26 mmol/L 1.3 (0.6) [n=253] 1.3 (0.6) [n=250]
TG, ≥2.26 mmol/L 2.6 (0.7) [n=52] 2.8 (0.6) [n=47]
Mean HDL-C (SD), mmol/L
Overall analysis cohort 1.4 (0.4) 1.4 (0.4)
TG, b2.26 mmol/L 1.5 (0.4) [n=253] 1.5 (0.4) [n=250]
TG, ≥2.26 mmol/L 1.2 (0.3) [n=52] 1.2 (0.3) [n=47]
Mean non-HDL-C (SD), mmol/L
Overall analysis cohort 3.9 (0.6) 4.0 (0.6)
TG, b2.26 mmol/L 3.8 (0.5) [n=253] 3.8 (0.5) [n=250]
TG, ≥2.26 mmol/L 4.5 (0.5) [n=52] 4.6 (0.5) [n=47]
Mean Apo B (SD), g/L
Overall analysis cohort 1.2 (0.2) 1.2 (0.2)
TG, b2.26 mmol/L 1.2 (0.2) [n=251] 1.1 (0.2) [n=246]
TG, ≥2.26 mmol/L 1.3 (0.2) [n=50] 1.4 (0.2) [n=46]
Apo indicates apolipoprotein; CHD, coronary heart disease; LDL-C, low-density
lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-
sensitivity C-reactive protein; TG, triglyceride.
Standard deviation for median is calculated by (Q3−Q1)/1.075.
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analyses reported herein were performed in the full analysis set
population (n=602) which included all randomized patients who
had baseline vales, had received at least 1 dose of studymedication, and
had a 6 week value. In total, 593 patients (of 618 studyparticipants) had
pairedbaselineandweek6values forApoBand LDL-CorApoBandnon-
HDL-C (i.e., referred to in the text as the overall cohort). Additional
analyses were performed in patient subgroups deﬁned by baseline TG
values b2.26 mmol/L (i.e., normal or borderline-high TG; n=497) and
N2.26 mmol/L (i.e., hypertriglyceridemic; n=96).
Changes from baseline in lipids, lipoproteins, and apolipoproteins
were calculatedusingananalysis-of-variance (ANOVA)modelwith terms
for treatment, stratum (according to potency of the prerandomization
statin brand/dose), baseline lipid value under assessment, and study
center. Within- and between-group least squares (LS) means and 95%
conﬁdence intervals (CIs)were estimated from theANOVAmodel. A non-
parametric ANOVAanalysiswas performed for TGbecause this parameter
is not normally distributed. The differences between treatment groups
were quantiﬁed using the difference in medians and 95% CIs using
Hodges–Lehmann for estimates.
The overall distributions of Apo B and LDL-C or non-HDL-C were
explored with scatter plots of Apo B versus LDL-C or non-HDL-C at
baseline and study end. Different colors and symbols were used to
differentiate the two treatment arms in these plots (i.e., red=EZE/
SIMVA, 10/20 mg; blue=ROSUVA, 10 mg). The correlations between
Apo B:LDL-C and Apo B:non-HDL-C were assessed using Pearson
correlation coefﬁcients. In addition, SLR analyses were performed to
explore the relationships between Apo B and LDL-C or non-HDL-C at
baseline and study end. The predicted values of LDL-C and non-HDL-C
corresponding to anApoB value of 0.9 g/Lwere calculated from the SLR.
All analyses were performed with SAS statistical software (version
9.1.3) at a two-sided signiﬁcance level of 0.05.
Analyses were performed to calculate the proportion of patients
achieving various LDL-C (b2.59, b1.99, and b1.81 mmol/L), non-HDL-C
(b3.37 and b2.59 mmol/L), and Apo B targets (b0.9 and b0.8 g/L). In
addition, of those who achieved a single speciﬁed LDL-C, non-HDL-C, or
Apo B target at study end, the proportions of patients who achieved the
second targetwere also analyzed. Rawproportions of patients achieving
these targets and the corresponding 95% conﬁdence interval (CI) based
on Wilson's method were reported. Target attainment analyses were
conducted in all patients who had week 6 data within each of the
treatment groups and broken down by baseline TG subgroup.
Results
The complete results of the INCROSS study have been reported
previously [12]. In this study of high-risk hypercholesterolemic patients
who did not achieve the minimum recommended LDL-C goal (i.e.,
≥2.59 mmol/L) while taking statin monotherapy, switching to EZE/
SIMVA10/20 mg comparedwith ROSUVA10 mgwas shown to produce
signiﬁcantly greater LS mean reductions from baseline in LDL-C (27.7%
versus 16.9%; pb0.001), non-HDL-C (23.4% versus 14.0%; pb0.001), and
Apo B (17.9% versus 9.8%; pb0.001) after 6 weeks of double-blind
treatment [12]. The demographic and lipid characteristics for the cohort
of patients included in the current post-hoc analysis are presented in
Table 1. The treatment groups were generally well-balanced with
respect to baseline demographic and lipid/lipoprotein characteristics
(Table 1). Patients with hypertriglyceridemia (TG, N2.27 mmol/L) had a
higher mean body weight and body mass index compared with non-
hypertriglyceridemic patients. A greater proportion of patients in the TG
N2.26 mmol/L subgrouphad a history of type 2 diabetes as evidenced by
their lipid/lipoprotein proﬁle (i.e., elevatedTGandApoB levelswith low
HDL-C levels).
The overall distributions of Apo B versus LDL-C and non-HDL-C for
patientswith paired data at baseline and study end are plotted in Figs. 1
and 2, respectively. An SLR model was ﬁtted and the results aresummarized in Tables 2 and 3, respectively. The relationships between
Apo B:LDL-C and Apo B:non-HDL-C were well described by linear
regression lines both following treatment with a stable dose of statin
monotherapy (i.e., baseline) and after switching to a more potent lipid-
lowering therapy (i.e., study end). The similarities in the regression line
characteristics and r2 values (Pearson correlation coefﬁcients) across
statin potency strata (i.e., low/high) at baseline demonstrated that the
relationships between Apo B and LDL-C or non-HDL-C appeared to be
independent of the LDL-C-lowering potency of the statin monotherapy
received during the open-label run-in phase of the study (data not
shown). Therefore, data from both strata were pooled in all subsequent
Fig. 1. Scatterplots of Apo B versus LDL-C at baseline (A) and following 6 weeks of treatment with EZE/SIMVA 10/20 mg or ROSUVA 10 mg (B). The upper thresholds for the less-
stringent LDL-C b2.59 mmol/L and Apo B b0.9 g/L targets are denoted by horizontal and vertical lines, respectively. Right lower quadrant in (B) shows the subjects who met LDL-C
goal b2.59 mmol/L but did not reach Apo B value b0.9 g/L. EZE/SIMVA indicates ezetimibe/simvastatin; ROSUVA, rosuvastatin; LDL-C, low-density lipoprotein cholesterol; Apo,
apolipoprotein.
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lipid-lowering therapyon the relationships between the lipoprotein and
lipid parameters. A single regression line was calculated for all statin-
treated patients at baseline (Figs. 1A and 2A),whereas 2 regression lines
were calculated for the individual treatment arms at study end (Figs. 1B
and 2B).Fig. 2. Scatterplots of Apo B versus non-HDL-C at baseline (A) and following 6 weeks of treatm
stringent non-HDL-C b3.37 mmol/L and Apo B b0.9 g/L targets are denoted by horizontal an
non-HDL-C goal b3.37 mmol/L but did not reach Apo B target b0.9 g/L. EZ/SIMVA indicates e
cholesterol; Apo, apolipoprotein.For the study entry criteria, patients were required to have an LDL-C
value in the range of 2.59–4.14 mmol/L after receiving a stable dose of
open-label statin monotherapy during the run-in period in order to be
eligible for enrollment. As a result, the majority of the data points at
baseline fell within the upper right quadrant of the Apo B versus LDL-C
and Apo B versus non-HDL-C scatter plots (Figs. 1A and 2A,ent with EZE/SIMVA 10/20 mg or ROSUVA 10 mg (B). The upper thresholds for the less-
d vertical lines, respectively. Right lower quadrant in (B) shows the subjects who met
zetimibe/simvastatin; ROSUVA, rosuvastatin; non-HDL-C, non-high-density lipoprotein
Table 2
Slope, intercept, Pearson correlation coefﬁcient, and predicted LDL-C values based on simple linear regression analyses of Apo B versus LDL-C at baseline (i.e., while on stable dose of
statin monotherapy) and following 6 weeks of treatment with EZE/SIMVA 10/20 mg or ROSUVA 10 mg.
N Slope Intercept Pearson correlation coefﬁcient (r2) Predicted LDL-C valuea
Baseline (i.e., while on stable dose of statin monotherapy)
Pooled treatment groups
Overall analysis cohort 593 1.15 1.85 0.550 (0.30) 2.9
TG, b2.26 mmol/L 497 1.27 1.73 0.566 (0.32) 2.9
TG, ≥2.26 mmol/L 96 1.26 1.55 0.589 (0.35) 2.7
Week 6 (i.e., after switching from statin monotherapy to EZE/SIMVA or ROSUVA)
Pooled treatment groups
Overall analysis cohort 593 2.61 −0.17 0.854 (0.73) 2.2
TG, b2.26 mmol/L 497 2.70 −0.21 0.881 (0.78) 2.2
TG, ≥2.26 mmol/L 96 2.62 −0.48 0.820 (0.67) 1.9
EZE/SIMVA, 10/20 mg
Overall analysis cohort 301 2.43 −0.06 0.829 (0.69) 2.1
TG, b2.26 mmol/L 251 2.59 −0.15 0.873 (0.76) 2.2
TG, ≥2.26 mmol/L 50 2.25 −0.21 0.771 (0.59) 1.8
ROSUVA, 10 mg
Overall analysis cohort 292 2.68 −0.17 0.867 (0.75) 2.2
TG, b2.26 mmol/L 246 2.73 −0.18 0.883 (0.78) 2.3
TG, ≥2.26 mmol/L 46 2.77 −0.53 0.851 (0.72) 2.0
EZE/SIMVA indicates ezetimibe/simvastatin; ROSUVA, rosuvastatin; TG, triglyceride.
a Predicted LDL-C value (mmol/L) assuming Apo B value of 0.9 g/L.
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minimum recommended targets of 0.9 g/L for Apo B and 2.59 mmol/L
for LDL-C or 3.37 mmol/L for non-HDL-C. Six patients with an LDL-C
value slightly below the LDL-C entry threshold of 2.59 mmol/L were
enrolled in this study and received randomized treatment assignment.
Following treatment with EZE/SIMVA 10/20 mg or ROSUVA 10 mg, the
observed reductions in LDL-C and non-HDL-C led to a shift in the
distribution of the data points toward the lower left and right quadrants
which encompassed the LDL-C (Fig. 1B) and non-HDL-C targets
(Fig. 2B). The regression lines for the 2 treatment arms are identiﬁed
by different colors and symbols in Figs. 1B and 2B. Relative to baseline,
treatment with EZE/SIMVA and ROSUVA led to decreases in the scatter
of the data points (implying increases in correlations) and roughly a
doubling of the slopes for the Apo B versus LDL-C and non-HDL-C
regression lines at study end. The regression lines for the Apo B versus
LDL-C and non-HDL-C scatter plots were very similar across the 2
treatment groups with the EZE/SIMVA regression line falling slightly
underneath the line for ROSUVA in both scatter plots.Table 3
Slope, intercept, Pearson correlation coefﬁcient, and predicted non-HDL-C values based on
stable dose of statin monotherapy) and following 6 weeks of treatment with EZE/SIMVA 10
N Slope Intercept
Baseline (i.e., while on stable dose of statin monotherapy)
Pooled treatment groups
Overall analysis cohort 593 1.88 1.71
TG, b2.26 mmol/L 497 1.66 1.90
TG, ≥2.26 mmol/L 96 1.40 2.65
Week 6 (i.e., after switching from statin monotherapy to EZE/SIMVA or ROSUVA)
Pooled treatment groups
Overall analysis cohort 593 3.19 −0.08
TG, b2.26 mmol/L 497 3.19 −0.08
TG, ≥2.26 mmol/L 96 3.15 −0.02
EZE/SIMVA 10/20 mg
Overall analysis cohort 301 3.05 0.00
TG, b2.26 mmol/L 251 3.10 −0.04
TG, ≥2.26 mmol/L 50 2.85 0.19
ROSUVA, 10 mg
Overall analysis cohort 292 3.23 −0.07
TG, b2.26 mmol/L 246 3.21 −0.06
TG, ≥2.26 mmol/L 46 3.25 −0.03
EZE/SIMVA indicates ezetimibe/simvastatin; ROSUVA, rosuvastatin; TG, triglyceride.
a Predicted non-HDL-C (mmol/L) assuming Apo B value of 0.9 g/L.Both LDL-C and non-HDL-C were positively correlatedwith Apo B at
baselinewhile patients were taking a stable dose of statinmonotherapy
with rvaluesof 0.550 and0.690, respectively (Tables 2 and3). Switching
from statin monotherapy to the more potent EZE/SIMVA 10/20 mg or
ROSUVA 10 mg substantially increased the strength of the correlations
between Apo B:LDL-C and Apo B:non-HDL-C at study end compared
with baseline (Tables 2 and 3). At study end, the strength of the Apo B:
LDL-C (r2 values of 0.829 and 0.867, respectively) and ApoB:non-HDL-C
(r2 values of 0.908 and 0.930, respectively) correlations were similar
across the EZE/SIMVA and ROSUVA groups (Tables 2 and 3).
Theﬁtted linear regressionmodelswereused topredict themodeled
LDL-C and non-HDL-C values corresponding to Apo B value of 0.9 g/L. At
baseline (i.e., week 0), an Apo B value of 0.9 g/L corresponded to LDL-C
and non-HDL-C values that were close to the minimum recommended
LDL-C and non-HDL-C targets for high-risk CHD patients (i.e., 2.59 and
3.37 mmol/L, respectively) (Tables 2 and 3). At baseline, a mean Apo B
value of 0.9 g/L corresponded to mean LDL-C and non-HDL-C values of
2.89 mmol/L and 3.38 mmol/L for the pooled treatment groups,simple linear regression analyses of Apo B versus non-HDL-C at baseline (i.e., while on
/20 mg or ROSUVA 10 mg.
Pearson correlation coefﬁcient (r2) Predicted non-HDL-C valuea
0.690 (0.48) 3.4
0.650 (0.42) 3.4
0.559 (0.31) 3.9
0.922 (0.85) 2.8
0.926 (0.86) 2.8
0.896 (0.80) 2.8
0.908 (0.83) 2.7
0.914 (0.84) 2.8
0.869 (0.76) 2.8
0.930 (0.87) 2.8
0.932 (0.87) 2.8
0.915 (0.84) 2.9
632 H. Vaverkova et al. / Clinical Biochemistry 44 (2011) 627–634respectively. After switching to EZE/SIMVA or ROSUVA (i.e., week 6/
study end), the LDL-C and non-HDL-C values corresponding to an Apo B
of 90 mg/dL were closer to the more aggressive LDL-C and non-HDL-C
targets (i.e., 1.81 and 2.59 mmol/L, respectively) (Tables 2 and 3). At
study end, a mean Apo B value of 0.9 g/L corresponded to mean
predicted LDL-C andnon-HDL-Cvalues of 2.18 mmol/L and2.79 mmol/L
for the pooled treatment groups, respectively.
Analysis of TG subgroups b and N2.26 mmol/L showed similar
changes in the relationships of Apo Bwith LDL-C and non-HDL-Cwith an
overall strengthening of the correlations following treatment with EZE/
SIVMA 10/20 mg and ROSUVA 10 mg relative to baseline in both
subgroups (Tables2 and3). At studyend, the rvalues for theApoB:LDL-C
and Apo B:non-HDL-C correlations were somewhat weaker in the
subgroup of patients with baseline TG level N2.26 mmol/L versus those
with TG level b2.26 mmol/L bothwhen examined in the overall analysis
cohort and broken down by treatment group. For the subgroup of
patients with elevated baseline TG level N2.26 mmol/L, the baseline and
study end LDL-C values corresponding to an Apo B value of 0.9 g/L were
lower compared with the TG b2.26 mmol/L subgroup. The predicted
LDL-C value for the TG b2.26 mmol/L subgroup was similar to that seen
for the overall analysis cohort (i.e., 2.23 versus 2.18 mmol/L for the
pooled treatment groups, respectively) but lower than the minimum
recommended LDL-C goal of 2.59 mmol/L for high-risk CHD patients. In
contrast, the predicted LDL-C value for the TG N2.26 mmol/L subgroup
wassubstantially lower than that seen for the overall analysis cohort (i.e.,
1.88 versus 2.18 mmol/L for the pooled treatment groups, respectively)
and similar to the optional recommended LDL-C goal of 1.81 mmol/L for
high-risk CHD patients. For the subgroup of patients with an elevated
baseline TG level N2.26 mmol/L, the predicted baseline and study end
non-HDL-C values corresponding to an Apo B value of 0.9 g/L were
similar compared with those seen for the TG b2.26 mmol/L subgroup.
In general, numerically higher proportions of patients reached LDL-C
2.59 mmol/L, non-HDL-Cb3.37 mmol/L, andApoBb0.9 g/L targetswith
EZE/SIMVA 10/20 mg versus ROSUVA 10mg irrespective of baseline TG
level (Table 4). Among the patients who attained LDL-C 2.59 mmol/L or
non-HDL-C b3.37 mmol/L goals while taking EZE/SIMVA 10/20 mg or
ROSUVA 10 mg, only slightly more than half of them also reached the
Apo B target b0.9 g/L at study end (Table 4; Figs. 1 and 2). The
percentages of patients who attained these dual targets (i.e., LDL-C,
2.59 mmol/L, and Apo B, b0.9 g/L; non-HDL-C, 3.37 mmol/L, and Apo B,
0.9 g/L) did not differ across the two treatment groups. Thus, a large
proportion of patients in the EZE/SIMVA and ROSUVA groups remained
at increased risk of coronary events, especially among the subgroup of
patients with high baseline TG ≥2.26 mmol/L. In contrast, among the
patients who met the Apo B target b0.9 g/L with EZE/SIMVA 10/20 mg
orROSUVA10 mg, the vastmajority of themalsoachieved theminimum
recommended LDL-C and non-HDL-C goals (Table 5; Figs. 1 and 2).Table 4
Percentages of patients reaching various LDL-C, non-HDL-C, or Apo B targets who also achi
10 mg.
Percentages of patients reaching individual target
EZE/SIMVA, 10/20 mg ROSUVA, 10 mg
n/Na % (95% CI) n/Na % (95% CI
LDL-C, b2.59 mmol/L
All patients 221/305 72.5% (67.2, 77.2) 167/297 56.2% (50
TG, b2.26 mmol/L 178/253 70.4% (64.5, 75.6) 138/250 55.2% (49
TG, ≥2.26 mmol/L 43/52 82.7% (70.3, 90.6) 29/47 61.7% (47
Non-HDL-C, b3.37 mmol/L
All patients 227/305 74.4% (69.3, 79.0) 184/297 62.0% (56
TG, b2.26 mmol/L 190/253 75.1% (69.4, 80.0) 163/250 65.2% (59
TG, ≥2.26 mmol/L 37/52 71.2% (57.7, 81.7) 21/47 44.7% (31
Apo indicates apolipoprotein; EZE/SIMVA, ezetimibe/simvastatin; LDL-C, low-density lipo
rosuvastatin; TG, triglyceride.
a Number of patients achieving speciﬁed lipoprotein target out of the total number of pa
b Number of patients achieving Apo B value out of the total number of patients already hDiscussion
Most international and national lipid treatment guidelines consider
LDL-C the primary goal of hypolipidemic therapy (e.g., NCEP ATP III,
European,AHA/ACC) [1,16,18,29]. Inhypertriglyceridemic subjectswith
TGvalues≥2.26 mmol/L, non-HDL-C is considered a secondary target of
therapy as this parameter reﬂects the total amount of cholesterol
transported in all atherogenic lipoprotein particles [1]. Statin therapy
reduces plasma levels of LDL-C and non-HDL-C to amuch greater extent
compared with that seen for Apo B [4,10,32]. Although patients may
achieve the minimum recommended LDL-C or non-HDL-C goals while
taking statin therapy, many patients still have a high number of
atherogenic particles in the circulation and thus remain at increased risk
for future coronary events [7,32,35]. This is especially true for patients
with insulin resistance because they commonly have a greater number
of atherogenic particles than can be predicted based solely on their LDL-
C levels [3,17,31]. To this end, the ADA/ACCF statement endorses the
achievement of ApoB targets for patientswith cardiometabolic risk (i.e.,
0.9 g/L and b0.8 g/L for high and very high risk, respectively) in addition
to LDL-C and non-HDL-C goals [8].
The purposeof the INCROSS studywas to evaluate the lipid-lowering
efﬁcacy of switching from a lower potency statin monotherapy to the
usual recommended starting dose of EZE/SIMVA 10/20 mg or ROSUVA
10mg in a population of high-risk CHDpatientswhodid not achieve the
minimum recommended LDL-C goal (i.e., LDL-C, b2.59 mmol/L) despite
taking previous statin monotherapy [12]. The primary analysis of this
study showed that treatment with EZE/SIMVA 10/20 mg produced
signiﬁcantly largermean incremental reductions frombaseline in LDL-C
of 11%, non-HDL-C of 9%, and Apo B of 8% beyond that achieved with
ROSUVA 10 mg. The safety and tolerability proﬁles of EZE/SIMVA 10/
20 mg and ROSUVA 10mg were quite similar as described in the
primary publication of the INCROSS study [12].
The current post-hoc analysis of the INCROSS study showed linear
correlations between Apo B:LDL-C and Apo B:non-HDL-C both during
treatment with statin monotherapy and after switching to more potent
lipid-lowering therapy. The LDL-C-lowering potency of the treatment
did not appear to affect the strength of these correlations as
demonstrated by the similarity in the r values across the statin potency
strata at baseline (i.e., low/high) and between the EZE/SIMVA and
ROSUVA groups at study end. Nevertheless, the strengths of the Apo B:
LDL-C and Apo B:non-HDL-C correlations were substantially improved
after patientswere switched from lower potency statinmonotherapy to
higher potency EZE/SIMVA 10/20 mg or ROSUVA 10mg therapy. The
absence of divergence in the between-group ﬁndings at study end
suggests that the different mechanisms of actions of EZE/SIMVA and
ROSUVA (i.e., EZE/SIMVA lowers cholesterol via inhibition of cholesterol
biosynthesis and absorption while ROSUVA lowers cholesterol viaeved Apo B b0.9 g/L after 6 weeks of treatment with EZE/SIMVA 10/20 mg or ROSUVA
Percentages of patients at LDL-C or non-HDL-C target who also
reached Apo B b0.9 g/L
EZE/SIMVA, 10/20 mg ROSUVA, 10 mg
) n/Nb % (95% CI) n/Nb % (95% CI)
.5, 61.8) 126/217 58.1% (51.4, 64.4) 98/166 59.0% (51.4, 66.2)
.0, 61.2) 114/176 64.8% (57.5, 71.5) 88/137 64.2% (55.9, 71.8)
.4, 74.2) 12/41 29.3% (17.6, 44.5) 10/29 34.5% (19.9, 52.7)
.3, 67.3) 128/223 57.4% (50.8, 63.7) 99/183 54.1% (46.9, 61.2)
.1, 70.8) 116/188 61.7% (54.6, 68.4) 90/162 55.6% (47.9, 63.0)
.4, 58.8) 12/35 34.3% (20.8, 50.9) 9/21 42.9% (24.5, 63.5)
protein cholesterol; non-HDL-C, non-high-density lipoprotein cholesterol; ROSUVA,
tients in the treatment group with efﬁcacy measurement.
aving achieved speciﬁed lipoprotein goals in each treatment group.
Table 5
Percentages of patients at an Apo B target of b0.9 g/L who also reached LDL-C or non-HDL-C goals after 6 weeks of treatment with EZE/SIMVA 10/20 mg or ROSUVA 10 mg.
Percentages of patients reaching Apo B b0.9 g/L target Percentages of patients at Apo B b0.9 g/L target who also reached LDL-
C or non-HDL-C target
EZE/SIMVA, 10/20 mg ROSUVA, 10 mg EZE/SIMVA, 10/20 mg ROSUVA, 10 mg
n/Na % (95% CI) n/Na % (95% CI) n/Nb % (95% CI) n/Nb % (95% CI)
Apo B, b0.9 g/L LDL-C, b2.59 mmol/L
All patients 128/301 42.5% (37.1, 48.2) 100/292 34.2% (29.0, 39.9) 126/128 98.4% (94.5, 99.6) 98/100 98.0% (93.0, 99.5)
TG, b2.26 mmol/L 116/251 46.2% (40.2, 52.4) 90/246 36.6% (30.8, 42.8) 114/116 98.3% (93.9, 99.5) 88/90 97.8% (92.3, 99.4)
TG, b2.26 mmol/L 12/50 24.0% (14.3, 37.4) 10/46 21.7% (12.3, 35.6) 12/12 100% (75.8, 100) 10/10 100% (75.3, 100)
Apo B, b0.9 g/L Non-HDL-C, b3.37 mmol/L
All patients 128/301 42.5% (37.1, 48.2) 100/292 34.2% (29.0, 39.9) 128/128 100% (97.1, 100) 99/100 99.0% (94.6, 99.8)
TG, b2.26 mmol/L 116/251 46.2% (40.2, 52.4) 90/246 36.6% (30.8, 42.8) 116/116 100% (96.8, 100) 90/90 100% (95.9, 100)
TG, b2.26 mmol/L 12/50 24.0% (14.3, 37.4) 10/46 21.7% (12.3, 35.6) 12/12 100% (75.8, 100) 9/10 90.0% (59.6, 98.2)
Apo indicates apolipoprotein; EZE/SIMVA, ezetimibe/simvastatin; LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non-high-density lipoprotein cholesterol; ROSUVA,
rosuvastatin; TG, triglyceride.
a Number of patients achieving speciﬁed lipoprotein target out of the total number of patients in the treatment group with efﬁcacy measurement.
b Number of patients achieving Apo B value out of the total number of patients already having achieved speciﬁed lipoprotein goals in each treatment group.
633H. Vaverkova et al. / Clinical Biochemistry 44 (2011) 627–634inhibition of cholesterol biosynthesis only) did not translate to
differences in the correlations or linear characteristics describing the
relationships between Apo B and LDL-C or Apo B and non-HDL-C to any
measurable degree.
Previous studies also demonstrated linear relationships and strong
correlations between Apo B:LDL-C and Apo B:non-HDL-C in untreated
as well as statin-treated patients [4,6,9]. In these prior studies, the
strength of the Apo B:LDL-C and Apo B:non-HDL-C correlations were
more robust in statin-treated patients compared with untreated
patients. The results of the current analysis build upon these previous
ﬁndings, demonstrating that combination therapy with EZE/SIMVA
alters the relationships between Apo B and LDL-C as well as non-HDL-C
in a manner similar to that seen with ROSUVA monotherapy. Marked
changes in the slopes of the linear regression lines were observed at
study end, indicating that Apo B particles became less lipid rich after
patients were switched from less intensive statinmonotherapy tomore
potent treatment with EZE/SIMVA and ROSUVA. These results can be
explained by Cromwell et al. [11] who demonstrated that LDL particles,
as assessed by nuclear magnetic resonance methodology, are more
cholesterol depletedwhen LDL-C concentrations are lower independent
of LDL particle size. These ﬁndings explain why patients with low LDL-C
levels often have disproportionately higher numbers of LDL particles
and thus plasma Apo B levels.
Of note, the r values observed in the current analysis among statin-
treated patients at baselinewere similar to those previously reported in
untreated patients [6]. The reason underlying this observation may in
part be due to variation in LDL-C entry criteria between the studies. The
range of LDL-C values in the INCROSS study was more restricted (2.59–
4.14 mmol/L) compared with that seen in theMERCURY II study (3.37–
6.48 mmol/L) [5,12].
Comparedwith LDL-C, non-HDL-C correlated betterwith Apo B both
at baseline while patients were taking statin monotherapy and at study
end following 6 weeks of treatment with EZE/SIMVA 10/20 mg and
ROSUVA 10 mg. These ﬁndings conﬁrm those of previous studies
showing that non-HDL-C levels are better correlated with Apo B
compared with LDL-C in statin-treated patients and extend this
observation to include EZE/SIMVA combination therapy [4,6,9].
At baseline, the mean predicted LDL-C and non-HDL-C levels
corresponding to an Apo B value of 0.9 g/L (i.e., 2.87 mmol/L and
3.38 mmol/L, respectively)were similar to theminimumrecommended
LDL-C (i.e., b2.59 mmol/L) and non-HDL-C (i.e., b3.37 mmol/L) targets
for high risk patients according to the NCEP ATP III guidelines [1]. After
switching from less potent statin monotherapy to more potent EZE/
SIMVA 10/20 mg or ROSUVA 10 mg therapy, the predicted LDL-C and
HDL-C values corresponding to an Apo B value of 0.9 g/L (i.e.,
2.17 mmol/L and 2.79 mmol/L, respectively) for the overall pooledpopulationwere closer to themore stringent LDL-C (i.e., b1.81 mmol/L)
and non-HDL-C (i.e., b2.59 mmol/L) targets for high risk patients [18].
Of note, the predicted LDL-C and non-HDL-C values were similar
between EZE/SIMVA and ROSUVA groups at study end, indicating that
these treatments had similar effects on the characteristics of the
modeled linear relationships between Apo B:LDL-C and Apo B:non-
HDL-C. Taken together, these data suggest that more aggressive LDL-C
and non-HDL-C targets must be achieved in order to normalize the
concentration of Apo B-containing atherogenic lipoproteins in this
populationofhigh-riskCHDpatientswho failed to attain theirminimum
recommended LDL-C goal with prior statin monotherapy.
When the linear regression analyses were examined by baseline TG,
the predicted LDL-C values corresponding to an Apo B value of 0.9 g/L
were consistently lower (by 0.2–0.4 mmol/L) in hypertriglyceridemic
compared with normotriglyceridemic patients. Furthermore, this
ﬁndingwas observed irrespective of treatment (i.e., statinmonotherapy
at baseline aswell as EZE/SIMVA and ROSUVA at study end). In contrast,
the predicted non-HDL-C levels for subjectswith high and low TG levels
were nearly identical across the EZE/SIMVA and ROSUVA groups at
study end. This observation is not surprising given that, unlikenon-HDL-
C, LDL-C is known to underestimate the number of atherogenic
lipoprotein particles in the circulation due to the preponderance of
small, dense, cholesterol depleted LDL particles in hypertriglyceridemic
patients [3,17,21,31]. As a result, larger reductions from baseline in LDL-
C are required to reach optimal Apo B levels in patients with high TG
levels.
The target attainment analyses demonstrated excellent congruence
between the LDL-C and non-HDL-C goal attainment rates among
patients who had achieved Apo B value b0.9 g/L at study end (i.e., 90%
of patients with Apo B b0.9 g/L also had LDL-C b2.59 mmol/L or non-
HDL-C b3.37 mmol/L in both the EZE/SIMVA and ROSUVA groups). The
proportions of patients who achieved these dual Apo B/LDL-C and Apo
B/non-HDL-C targets did not differ across the EZE/SIMVA and ROSUVA
groups and among patients with low and high TG values at baseline. In
contrast, only slightly more than half of the patients who reached an
LDL-C level b2.59 mmol/L or non-HDL-C level b3.37 mmol/L at study
end also had an Apo B level b0.9 g/L following treatment with EZE/
SIMVA or ROSUVA.
Conclusion
Taken together, the correlation and linear regression analyses
suggest that much lower LDL-C and non-HDL-C levels are required to
obtain a desirable number of atherogenic particles (i.e., attainment of
Apo B target levels) following aggressive lipid lowering treatment with
EZE/SIMVA and ROSUVA. Goal attainment analysis shows that
634 H. Vaverkova et al. / Clinical Biochemistry 44 (2011) 627–634substantial number of patients reaching the recommended LDL-C and
non-HDL-C goals for high risk patients were not at the minimum Apo B
target of 0.9 g/L. This ﬁnding was especially true for the subgroup of
patients with high baseline triglyceride levels. In contrast, treating
patients to theApoB target of b0.9 g/L ensured concurrent achievement
of LDL-C and non-HDL-C goals in both normotriglyceridemic and
hypertriglyceridemic patients.
Apo B measurements can be performed by most high volume
analyzers which are available in most laboratories and have been
standardized (with use of international reference material) by the
World Health Organization [10]. This parameter does not need to be
measured in the fasting state and is not inﬂuenced by hypertriglycer-
idemia up to 10 mmol/L.
The results of the current analysis suggest that Apo B is a good
marker for monitoring the efﬁcacy of lipid lowering therapy. The use of
Apo B tomonitor treatment efﬁcacywould likely lead tomore stringent
criteria for LDL-C lowering. In those instances where Apo B cannot be
measured, non-HDL-Cmay beused as a surrogatemarker. Nevertheless,
a non-HDL-C goal b2.59 mmol/L should be used to ensure achievement
of the minimum recommended Apo B level (i.e., 0.9 g/L) and normalize
the atherogenic particle number.References
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